Singular Genomics Systems (Singular Genomics Systems) Retained Earnings : $-362.62 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Singular Genomics Systems Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Singular Genomics Systems's retained earnings for the quarter that ended in Mar. 2024 was $-362.62 Mil.

Singular Genomics Systems's quarterly retained earnings declined from Sep. 2023 ($-314.35 Mil) to Dec. 2023 ($-337.60 Mil) and declined from Dec. 2023 ($-337.60 Mil) to Mar. 2024 ($-362.62 Mil).

Singular Genomics Systems's annual retained earnings declined from Dec. 2021 ($-151.90 Mil) to Dec. 2022 ($-242.78 Mil) and declined from Dec. 2022 ($-242.78 Mil) to Dec. 2023 ($-337.60 Mil).

Singular Genomics Systems Retained Earnings Historical Data

The historical data trend for Singular Genomics Systems's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Singular Genomics Systems Retained Earnings Chart

Singular Genomics Systems Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

-25.18

-53.13

-151.90

-242.78

-337.60

Singular Genomics Systems Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Retained Earnings	Get a 7-Day Free Trial													-266.41	-291.99	-314.35	-337.60	-362.62

Singular Genomics Systems Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Singular Genomics Systems (NAS:OMIC) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Singular Genomics Systems (Singular Genomics Systems) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Singular Genomics Systems Inc (NAS:OMIC) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

3010 Science Park Road, San Diego, CA, USA, 92121

Website

https://www.singulargenomics.com

Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.

Executives

Andrew Spaventa	director, 10 percent owner, officer: Chief Executive Officer	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Eli N. Glezer	officer: Chief Scientific Officer	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Jyotsna Ghai	officer: Chief Operating Officer	3010 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Kim P. Kamdar	director	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Marcia Eisenberg	director	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Sam Ropp	officer: Chief Commercial Officer	3010 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Michael J Pellini	director	222 DUTTON MILL RD, WILLISTOWN PA 19380
Elaine R Mardis	director	301 MERRITT 7, NORWALK CT 06851
James E Flynn	10 percent owner, other: *Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
David Daly	officer: President and Chief Operating	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Vincent Brancaccio	officer: Vice President, HR	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Dalen Meeter	officer: Vice President, Finance	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Daralyn Durie	officer: General Counsel	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Jorge Velarde	officer: Senior Vice President	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
David L Barker	director	9885 TOWNE CENTRE DR, SAN DIEGO CA 92121